The End of an Era: FDA Announces Disposition Plans for COVID

The COVID-19 pandemic presented the U.S. Food and Drug Administration (FDA or Agency) with a monumental task of shifting its operations and the way it approached the regulation of...

Related Keywords

, Health Care Professionals , Public Health Emergency On Formal Meetings , Drug Administration , Development Of Abbreviated New Drug Applications During , Public Health Emergency , Public Health Emergency Revised , Health Emergency , Federal Register , Guidance Documents That Will Expire With , Transition Plan , Investigational Cellular , Gene Therapy Products During , Abbreviated New Drug Applications During , Formal Meetings , User Fee Applications Questions , Certain Drugs , Hospitalized Patients , Outsourcing Facilities During , General Considerations , Biological Products , Quite Finished , Guidance Documents That Will Remain , Supply Chain , Biological Product Inspections During , Health Emergency Questions , Face Shields , Surgical Masks , Respirators During , Gloves During , Molecular Influenza , Emergency Use Authorizations , Use Authorization , Clinical Trials , Medical Products During , Review Board , Individual Patient Expanded Access Requests , Investigational New Drugs , Biological Products During , Health Emergency Guidance , Clinical Investigators , Interactive Evaluations , Drug Manufacturing , Bioresearch Monitoring Facilities During , Approved Premarket Approval , Humanitarian Device Exemption Submissions During , Long Haul , Guidance Documents Not Impacted , Specific Guidance , Adverse Event Reporting , Medical Products , Dietary Supplements During , Evaluating Impact , Viral Mutations ,